Business
Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) (the “Lexeo”), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that it has commenced an underwritten public offering and concurrent private placement of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, Lexeo intends to grant the under
About this update from Lexeo Therapeutics, Inc.
[{"type":"image","alt":"Lexeo Therapeutics","displaySize":"","headline":null,"caption":"Lexeo Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":116,"url":"https://media.zenfs.com/en/globenewswire.com/12a596ea7105503183002156834260ac"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZNNLd9kZ10lMRyd7r.aoKQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/12a596ea7105503183002156834260ac","width":300,"height":116}},"lazy":false},{"type":"text","content":"NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) (the “Lexeo”), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that it has commenced an underwritten public offering and concurrent private placement of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, Lexeo intends to grant the underwriters a 30-day option to purchase additional shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in the proposed offering will be sold by Lexeo.","length":691,"tagName":"p"},{"type":"text","content":"Concurrent with the proposed public offering, Lexeo intends to sell shares of its common stock, and, in lieu of common stock, pre-funded warrants to purchase shares of its common stock, to Balyasny Asset Management in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended, subject to consummation of the proposed public offering and other customary conditions. However, the consummation of the proposed public offering is not contingent on the consummation of the concurrent private placement.","length":543,"tagName":"p"},{"type":"text","content":"The proposed public offering and concurrent private placement are subject to market and other conditions, and there can be no assurance as to whether or when the proposed public offering and concurrent private placement may be completed, or as to the actual size or terms of the proposed public offering and concurrent private placement.","length":337,"tagName":"p"},{"type":"text","content":"Leerink Partners, Cantor, Stifel and Oppenheimer & Co. are acting as joint book-running managers fo...